Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Offering SPR-BLI Services - Proteins provided for free!
Thank you for choosing ACROBiosystems. Would you rate our product and service？ Thank you for choosing ACROBiosystems. Would you rate our product and service？
Here come GMP Grade Cytokines！Free Sample is available！ Here come GMP Grade Cytokines！Free Sample is available！
5e5 of Anti-CLEC12A/CLL-1 CAR-293 cells were stained with 100 μL of 1:25 dilution (4 μL stock solution in 100 μL FACS buffer) of APC-Labeled Human CLEC12A Protein, His Tag, premium grade (Cat. No. CLA-HA246) and negative control protein respectively. APC signal was used to evaluate the binding activity (QC tested).
5e5 of anti-CLEC12A / CLL-1 CAR-293 cells were stained with 100 μL of 1:25 dilution (4 μL stock solution in 100 μL FACS buffer) of APC-Labeled Human CLEC12A, His Tag (Cat. No. CLA-HA248) and negative control protein respectively. APC signal was used to evaluate the binding activity (QC tested).
Immobilized Biotinylated Human CLEC12A Protein, Avitag,His Tag, premium grade (Cat. No. CLA-H82E6) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate, can bind Monoclonal Anti-Human CLEC12A Antibody, Human IgG1 with a linear range of 0.1-0.8 ng/mL (QC tested).
The purity of Human CLEC12A, Fc Tag (Cat. No. CLA-H5266) is more than 90% and the molecular weight of this protein is around 125-140 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| CD123/CLL1 CAR-T Cell Therapy (Fujian Medical University) | Phase 3 Clinical | Fujian Medical University | Leukemia, Myeloid, Acute | Details | |
| Anti-CLL1 CAR-T (Guangzhou Bio-Gene) | BG-1805; BG1805 | Phase 2 Clinical | Guangzhou Bio-Gene Technology Co Ltd | Leukemia; Leukemia, Myeloid, Acute | Details |
| Anti-CLL1 CAR T cell therapy(Soochow University) | Phase 2 Clinical | The First Affiliated Hospital Of Soochow University | Leukemia, Myeloid, Acute | Details | |
| ICG-136 | ICG-136; 123b-33bcCAR | Phase 1 Clinical | Icell Gene Therapeutics (Int'L) Ltd | Leukemia, Myeloid, Acute | Details |
| CLL-1.CAR T cell therapy (Baylor College of Medicine) | Phase 1 Clinical | Baylor College Of Medicine | Leukemia, Myeloid, Acute | Details | |
| DCLL-9718S | DCLL-9718S; MCLL-0517A; RG-6109 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Leukemia, Myeloid, Acute | Details |
| Anti-CLL-1 CAR NK cells Therapy(Shanghai General Hospital) | Phase 1 Clinical | Leukemia, Myeloid, Acute | Details | ||
| CLL1 and CD38 Dual CAR-T therapy(Gracell Biotechnologies) | Phase 1 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd, The 920th Hospital Of Joint Logistics Support Force Of PLA | Leukemia, Myeloid, Acute | Details | |
| Universal CAR-T Cells therapy(Shenzhen Geno-Immune Medical Institute) | Phase 1 Clinical | Shenzhen Geno-Immune Medical Institute | Leukemia, Myeloid, Acute | Details | |
| CLL1 CAR-NK cell (Zhejiang University/Hangzhou Qihangene Biotech) | Phase 1 Clinical | Zhejiang University, Hangzhou Qihan Jiyin Biotechnology Co Ltd | Leukemia, Myeloid, Acute | Details | |
| CD33/CLL1 dual CAR-NK cell therapy(Institute Of Hematology & Blood Diseases Hospital) | Phase 1 Clinical | Institute Of Hematology & Blood Diseases Hospital, Hangzhou Qihan Biotechnology Co Ltd | Neoplasm, Residual; Leukemia, Myeloid, Acute | Details | |
| CD371-YSNVZ-IL18 CAR T cells therapy | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Leukemia, Myeloid, Acute | Details | |
| CLL-1/CD33 Targeted LCAR-AMDR Cells（Nanjing Legend Biotechnology） | Phase 1 Clinical | Leukemia, Myeloid, Acute | Details | ||
| IBR-733 | IBR-733; IBR733 | Phase 1 Clinical | Imbioray (Hangzhou) Biomedicine Co Ltd | Leukemia, Myeloid, Acute | Details |
| CLL1 CAR-T(Zhejiang University) | Phase 1 Clinical | Zhejiang University | Leukemia, Myeloid, Acute | Details | |
| CLL1+CD33 CAR-T(Zhejiang University) | Phase 1 Clinical | Zhejiang University | Leukemia, Myeloid, Acute | Details | |
| CLL1 CAR T-cell Therapy(Yake Biotechnology) | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Leukemia, Myeloid, Acute | Details | |
| Anti-CD33/CLL1 CAR-NK Cell Therapy | Phase 1 Clinical | Imbioray (Hangzhou) Biomedicine Co Ltd | Leukemia, Myeloid, Acute | Details | |
| KITE-222 | Phase 1 Clinical | Leukemia, Myeloid, Acute | Details | ||
| Anti-CD33/CLL-1 CAR-T (Legend) | Phase 1 Clinical | Legend Biotech Corp | Leukemia, Promyelocytic, Acute | Details | |
| Tepoditamab | MCLA-117 | Phase 1 Clinical | Pharmaceutical Research Associates, Institute Gustave-Roussy, Merus Nv, Vu University Medical Center, Lgc | Leukemia, Myeloid, Acute | Details |
| CD123/CLL1 CAR-T Cell Therapy (Fujian Medical University) | Phase 3 Clinical | Fujian Medical University | Leukemia, Myeloid, Acute | Details | |
| Anti-CLL1 CAR-T (Guangzhou Bio-Gene) | BG-1805; BG1805 | Phase 2 Clinical | Guangzhou Bio-Gene Technology Co Ltd | Leukemia; Leukemia, Myeloid, Acute | Details |
| Anti-CLL1 CAR T cell therapy(Soochow University) | Phase 2 Clinical | The First Affiliated Hospital Of Soochow University | Leukemia, Myeloid, Acute | Details | |
| ICG-136 | ICG-136; 123b-33bcCAR | Phase 1 Clinical | Icell Gene Therapeutics (Int'L) Ltd | Leukemia, Myeloid, Acute | Details |
| CLL-1.CAR T cell therapy (Baylor College of Medicine) | Phase 1 Clinical | Baylor College Of Medicine | Leukemia, Myeloid, Acute | Details | |
| DCLL-9718S | DCLL-9718S; MCLL-0517A; RG-6109 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Leukemia, Myeloid, Acute | Details |
| Anti-CLL-1 CAR NK cells Therapy(Shanghai General Hospital) | Phase 1 Clinical | Leukemia, Myeloid, Acute | Details | ||
| CLL1 and CD38 Dual CAR-T therapy(Gracell Biotechnologies) | Phase 1 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd, The 920th Hospital Of Joint Logistics Support Force Of PLA | Leukemia, Myeloid, Acute | Details | |
| Universal CAR-T Cells therapy(Shenzhen Geno-Immune Medical Institute) | Phase 1 Clinical | Shenzhen Geno-Immune Medical Institute | Leukemia, Myeloid, Acute | Details | |
| CLL1 CAR-NK cell (Zhejiang University/Hangzhou Qihangene Biotech) | Phase 1 Clinical | Zhejiang University, Hangzhou Qihan Jiyin Biotechnology Co Ltd | Leukemia, Myeloid, Acute | Details | |
| CD33/CLL1 dual CAR-NK cell therapy(Institute Of Hematology & Blood Diseases Hospital) | Phase 1 Clinical | Institute Of Hematology & Blood Diseases Hospital, Hangzhou Qihan Biotechnology Co Ltd | Neoplasm, Residual; Leukemia, Myeloid, Acute | Details | |
| CD371-YSNVZ-IL18 CAR T cells therapy | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Leukemia, Myeloid, Acute | Details | |
| CLL-1/CD33 Targeted LCAR-AMDR Cells（Nanjing Legend Biotechnology） | Phase 1 Clinical | Leukemia, Myeloid, Acute | Details | ||
| IBR-733 | IBR-733; IBR733 | Phase 1 Clinical | Imbioray (Hangzhou) Biomedicine Co Ltd | Leukemia, Myeloid, Acute | Details |
| CLL1 CAR-T(Zhejiang University) | Phase 1 Clinical | Zhejiang University | Leukemia, Myeloid, Acute | Details | |
| CLL1+CD33 CAR-T(Zhejiang University) | Phase 1 Clinical | Zhejiang University | Leukemia, Myeloid, Acute | Details | |
| CLL1 CAR T-cell Therapy(Yake Biotechnology) | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Leukemia, Myeloid, Acute | Details | |
| Anti-CD33/CLL1 CAR-NK Cell Therapy | Phase 1 Clinical | Imbioray (Hangzhou) Biomedicine Co Ltd | Leukemia, Myeloid, Acute | Details | |
| KITE-222 | Phase 1 Clinical | Leukemia, Myeloid, Acute | Details | ||
| Anti-CD33/CLL-1 CAR-T (Legend) | Phase 1 Clinical | Legend Biotech Corp | Leukemia, Promyelocytic, Acute | Details | |
| Tepoditamab | MCLA-117 | Phase 1 Clinical | Pharmaceutical Research Associates, Institute Gustave-Roussy, Merus Nv, Vu University Medical Center, Lgc | Leukemia, Myeloid, Acute | Details |
This web search service is supported by Google Inc.
アクロバイオシステムズの公式アカウント
A-Z
